United Therapeutics (NASDAQ:UTHR) Downgraded by Zacks Investment Research

Zacks Investment Research cut shares of United Therapeutics (NASDAQ:UTHR) from a buy rating to a hold rating in a research note released on Wednesday, Zacks.com reports. Zacks Investment Research currently has $86.00 price objective on the biotechnology company’s stock.

According to Zacks, “United Therapeutics beat on both earnings and sales in Q2. It holds a strong position in the PAH market. Demand for its treprostinil medicines — Remodulin, Tyvaso and Orenitram — remains strong despite generic concerns and competitive pressure. It is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Moreover, the company bought several new product candidates in 2018 to strengthen its pipeline. However, competition in the PAH market is increasing. Also, two of its biggest products — Remodulin and Adcirca —lost exclusivity in 2018. Generic versions of both the drugs have been launched, which could significantly erode the drugs’ sales in 2019. The stock has also underperformed the industry this year so far”

A number of other analysts have also commented on the company. ValuEngine upgraded United Therapeutics from a sell rating to a hold rating in a report on Thursday, August 1st. UBS Group upgraded United Therapeutics from a sell rating to a neutral rating and dropped their price target for the stock from $115.00 to $94.00 in a report on Friday, May 17th. They noted that the move was a valuation call. Wedbush reiterated a buy rating and set a $273.00 price target on shares of United Therapeutics in a report on Thursday, August 1st. BidaskClub upgraded United Therapeutics from a sell rating to a hold rating in a report on Tuesday, August 6th. Finally, Jefferies Financial Group upgraded United Therapeutics from an underperform rating to a hold rating and set a $90.00 price target on the stock in a report on Thursday, August 1st. One analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $120.36.

Shares of United Therapeutics stock opened at $81.37 on Wednesday. The business’s fifty day simple moving average is $78.95 and its 200 day simple moving average is $97.42. The firm has a market capitalization of $3.48 billion, a P/E ratio of 6.08 and a beta of 1.05. United Therapeutics has a 12 month low of $74.31 and a 12 month high of $130.00. The company has a current ratio of 4.62, a quick ratio of 4.41 and a debt-to-equity ratio of 0.31.

In other news, Director Richard Giltner sold 5,000 shares of United Therapeutics stock in a transaction on Thursday, June 20th. The stock was sold at an average price of $79.05, for a total value of $395,250.00. Following the completion of the transaction, the director now directly owns 5,000 shares in the company, valued at $395,250. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Raymond Dwek sold 3,750 shares of United Therapeutics stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $76.11, for a total value of $285,412.50. Following the completion of the transaction, the director now owns 3,750 shares of the company’s stock, valued at $285,412.50. The disclosure for this sale can be found here. Company insiders own 8.80% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. grew its position in shares of United Therapeutics by 1.1% in the first quarter. BlackRock Inc. now owns 4,994,759 shares of the biotechnology company’s stock valued at $586,236,000 after purchasing an additional 52,760 shares in the last quarter. Vanguard Group Inc. grew its position in shares of United Therapeutics by 0.8% in the second quarter. Vanguard Group Inc. now owns 3,988,515 shares of the biotechnology company’s stock valued at $311,343,000 after purchasing an additional 33,194 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of United Therapeutics by 35.7% in the second quarter. Renaissance Technologies LLC now owns 3,040,978 shares of the biotechnology company’s stock valued at $237,379,000 after purchasing an additional 799,200 shares in the last quarter. First Trust Advisors LP grew its position in shares of United Therapeutics by 7.8% in the first quarter. First Trust Advisors LP now owns 1,290,590 shares of the biotechnology company’s stock valued at $151,477,000 after purchasing an additional 93,786 shares in the last quarter. Finally, Dimensional Fund Advisors LP grew its position in shares of United Therapeutics by 2.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,088,982 shares of the biotechnology company’s stock valued at $118,583,000 after purchasing an additional 29,427 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.

Featured Story: Rule of 72

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.